PortalPublikationenCereblon gene expression and correlation with clinical outco...

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

Standard

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. / Qian, Xiaozhong; Dimopoulos, Meletios A; Amatangelo, Michael; Bjorklund, Chad; Towfic, Fadi; Flynt, Erin; Weisel, Katja C; Ocio, Enrique M; Yu, Xin; Peluso, Teresa; Sternas, Lars; Zaki, Mohamed; Moreau, Philippe; Thakurta, Anjan.

in: LEUKEMIA LYMPHOMA, Jahrgang 60, Nr. 2, 02.2019, S. 462-470.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Qian, X, Dimopoulos, MA, Amatangelo, M, Bjorklund, C, Towfic, F, Flynt, E, Weisel, KC, Ocio, EM, Yu, X, Peluso, T, Sternas, L, Zaki, M, Moreau, P & Thakurta, A 2019, 'Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS', LEUKEMIA LYMPHOMA, Jg. 60, Nr. 2, S. 462-470. https://doi.org/10.1080/10428194.2018.1485915

APA

Qian, X., Dimopoulos, M. A., Amatangelo, M., Bjorklund, C., Towfic, F., Flynt, E., Weisel, K. C., Ocio, E. M., Yu, X., Peluso, T., Sternas, L., Zaki, M., Moreau, P., & Thakurta, A. (2019). Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. LEUKEMIA LYMPHOMA, 60(2), 462-470. https://doi.org/10.1080/10428194.2018.1485915

Vancouver

Qian X, Dimopoulos MA, Amatangelo M, Bjorklund C, Towfic F, Flynt E et al. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. LEUKEMIA LYMPHOMA. 2019 Feb;60(2):462-470. https://doi.org/10.1080/10428194.2018.1485915

Bibtex

@article{7abfd5bf2bff4d6fbc457123d50b2dc9,
title = "Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS",
abstract = "We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials.gov: NCT01712789; EudraCT number: 2012-001888-78). Clinical responses were observed at all CRBN expression levels. A trend in progression-free survival (PFS; p = .038) and a potential trend in overall survival (OS; p = .059) favoring high CRBN expressers were observed; however, no notable difference in overall response rate (ORR) was observed. ORR (30%), median PFS (17.7 weeks), and median OS (52.3 weeks) in low-CRBN expressers were comparable to those in the STRATUS intent-to-treat population (ORR, 33%; median PFS, 20.0 weeks; median OS, 51.7 weeks). A trend in ORR (p = .050) favoring higher cMYC expressers was observed with no notable difference in PFS or OS. This analysis does not support exploring CRBN as a biomarker for selecting patients for pomalidomide therapy.",
keywords = "Journal Article",
author = "Xiaozhong Qian and Dimopoulos, {Meletios A} and Michael Amatangelo and Chad Bjorklund and Fadi Towfic and Erin Flynt and Weisel, {Katja C} and Ocio, {Enrique M} and Xin Yu and Teresa Peluso and Lars Sternas and Mohamed Zaki and Philippe Moreau and Anjan Thakurta",
year = "2019",
month = feb,
doi = "10.1080/10428194.2018.1485915",
language = "English",
volume = "60",
pages = "462--470",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "2",

}

RIS

TY - JOUR

T1 - Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

AU - Qian, Xiaozhong

AU - Dimopoulos, Meletios A

AU - Amatangelo, Michael

AU - Bjorklund, Chad

AU - Towfic, Fadi

AU - Flynt, Erin

AU - Weisel, Katja C

AU - Ocio, Enrique M

AU - Yu, Xin

AU - Peluso, Teresa

AU - Sternas, Lars

AU - Zaki, Mohamed

AU - Moreau, Philippe

AU - Thakurta, Anjan

PY - 2019/2

Y1 - 2019/2

N2 - We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials.gov: NCT01712789; EudraCT number: 2012-001888-78). Clinical responses were observed at all CRBN expression levels. A trend in progression-free survival (PFS; p = .038) and a potential trend in overall survival (OS; p = .059) favoring high CRBN expressers were observed; however, no notable difference in overall response rate (ORR) was observed. ORR (30%), median PFS (17.7 weeks), and median OS (52.3 weeks) in low-CRBN expressers were comparable to those in the STRATUS intent-to-treat population (ORR, 33%; median PFS, 20.0 weeks; median OS, 51.7 weeks). A trend in ORR (p = .050) favoring higher cMYC expressers was observed with no notable difference in PFS or OS. This analysis does not support exploring CRBN as a biomarker for selecting patients for pomalidomide therapy.

AB - We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials.gov: NCT01712789; EudraCT number: 2012-001888-78). Clinical responses were observed at all CRBN expression levels. A trend in progression-free survival (PFS; p = .038) and a potential trend in overall survival (OS; p = .059) favoring high CRBN expressers were observed; however, no notable difference in overall response rate (ORR) was observed. ORR (30%), median PFS (17.7 weeks), and median OS (52.3 weeks) in low-CRBN expressers were comparable to those in the STRATUS intent-to-treat population (ORR, 33%; median PFS, 20.0 weeks; median OS, 51.7 weeks). A trend in ORR (p = .050) favoring higher cMYC expressers was observed with no notable difference in PFS or OS. This analysis does not support exploring CRBN as a biomarker for selecting patients for pomalidomide therapy.

KW - Journal Article

U2 - 10.1080/10428194.2018.1485915

DO - 10.1080/10428194.2018.1485915

M3 - SCORING: Journal article

C2 - 30068263

VL - 60

SP - 462

EP - 470

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 2

ER -